Role of inhibitors of mammalian target of rapamycin in the treatment of luminal breast cancer

Eva Ciruelos, Hernán Cortes-Funes, Ismael Ghanem, Luis Manso, Carlos Arteaga

Research output: Contribution to journalReview article

11 Citations (Scopus)

Abstract

Approximately 75% of patients with breast cancer present hormone receptor-positive tumors. This subtype of breast cancer initially shows a high overall response rate to hormonal treatments. However, resistance eventually develops, resulting in tumor progression. The PI3K/Akt/mTOR pathway regulates several cellular functions in cancer such as cell growth, survival, and proliferation. In addition, a high activation level of the PI3K/Akt/mTOR pathway is related to resistance to conventional chemotherapy and hormone therapy. The mTOR inhibitor everolimus, in combination with hormonal treatments, has led to excellent results in progression-free survival in patients with metastatic breast cancer resistant to hormone therapies. Therefore, everolimus has entered the National Comprehensive Cancer Network (NCCN) guidelines 2012 and its combination with exemestane was approved recently by the US Food and Drug Administration and the European Medicines Agency. This is the first time that a drug will have been approved for the restoration of hormone sensitivity in breast cancer.

Original languageEnglish (US)
Pages (from-to)769-780
Number of pages12
JournalAnti-Cancer Drugs
Volume24
Issue number8
DOIs
StatePublished - Sep 1 2013

Fingerprint

Sirolimus
Hormones
Breast Neoplasms
exemestane
Phosphatidylinositol 3-Kinases
Neoplasms
United States Food and Drug Administration
Therapeutics
Disease-Free Survival
Cell Survival
Cell Proliferation
Guidelines
Drug Therapy
Growth
Pharmaceutical Preparations
Everolimus

Keywords

  • breast cancer
  • estrogen receptor
  • everolimus
  • human epidermal growth factor receptor 2
  • mammalian target of rapamycin

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Cancer Research
  • Oncology

Cite this

Role of inhibitors of mammalian target of rapamycin in the treatment of luminal breast cancer. / Ciruelos, Eva; Cortes-Funes, Hernán; Ghanem, Ismael; Manso, Luis; Arteaga, Carlos.

In: Anti-Cancer Drugs, Vol. 24, No. 8, 01.09.2013, p. 769-780.

Research output: Contribution to journalReview article

Ciruelos, Eva ; Cortes-Funes, Hernán ; Ghanem, Ismael ; Manso, Luis ; Arteaga, Carlos. / Role of inhibitors of mammalian target of rapamycin in the treatment of luminal breast cancer. In: Anti-Cancer Drugs. 2013 ; Vol. 24, No. 8. pp. 769-780.
@article{253a885185ce4cba82cf6d0e86c3b1db,
title = "Role of inhibitors of mammalian target of rapamycin in the treatment of luminal breast cancer",
abstract = "Approximately 75{\%} of patients with breast cancer present hormone receptor-positive tumors. This subtype of breast cancer initially shows a high overall response rate to hormonal treatments. However, resistance eventually develops, resulting in tumor progression. The PI3K/Akt/mTOR pathway regulates several cellular functions in cancer such as cell growth, survival, and proliferation. In addition, a high activation level of the PI3K/Akt/mTOR pathway is related to resistance to conventional chemotherapy and hormone therapy. The mTOR inhibitor everolimus, in combination with hormonal treatments, has led to excellent results in progression-free survival in patients with metastatic breast cancer resistant to hormone therapies. Therefore, everolimus has entered the National Comprehensive Cancer Network (NCCN) guidelines 2012 and its combination with exemestane was approved recently by the US Food and Drug Administration and the European Medicines Agency. This is the first time that a drug will have been approved for the restoration of hormone sensitivity in breast cancer.",
keywords = "breast cancer, estrogen receptor, everolimus, human epidermal growth factor receptor 2, mammalian target of rapamycin",
author = "Eva Ciruelos and Hern{\'a}n Cortes-Funes and Ismael Ghanem and Luis Manso and Carlos Arteaga",
year = "2013",
month = "9",
day = "1",
doi = "10.1097/CAD.0b013e328363adc5",
language = "English (US)",
volume = "24",
pages = "769--780",
journal = "Anti-Cancer Drugs",
issn = "0959-4973",
publisher = "Lippincott Williams and Wilkins",
number = "8",

}

TY - JOUR

T1 - Role of inhibitors of mammalian target of rapamycin in the treatment of luminal breast cancer

AU - Ciruelos, Eva

AU - Cortes-Funes, Hernán

AU - Ghanem, Ismael

AU - Manso, Luis

AU - Arteaga, Carlos

PY - 2013/9/1

Y1 - 2013/9/1

N2 - Approximately 75% of patients with breast cancer present hormone receptor-positive tumors. This subtype of breast cancer initially shows a high overall response rate to hormonal treatments. However, resistance eventually develops, resulting in tumor progression. The PI3K/Akt/mTOR pathway regulates several cellular functions in cancer such as cell growth, survival, and proliferation. In addition, a high activation level of the PI3K/Akt/mTOR pathway is related to resistance to conventional chemotherapy and hormone therapy. The mTOR inhibitor everolimus, in combination with hormonal treatments, has led to excellent results in progression-free survival in patients with metastatic breast cancer resistant to hormone therapies. Therefore, everolimus has entered the National Comprehensive Cancer Network (NCCN) guidelines 2012 and its combination with exemestane was approved recently by the US Food and Drug Administration and the European Medicines Agency. This is the first time that a drug will have been approved for the restoration of hormone sensitivity in breast cancer.

AB - Approximately 75% of patients with breast cancer present hormone receptor-positive tumors. This subtype of breast cancer initially shows a high overall response rate to hormonal treatments. However, resistance eventually develops, resulting in tumor progression. The PI3K/Akt/mTOR pathway regulates several cellular functions in cancer such as cell growth, survival, and proliferation. In addition, a high activation level of the PI3K/Akt/mTOR pathway is related to resistance to conventional chemotherapy and hormone therapy. The mTOR inhibitor everolimus, in combination with hormonal treatments, has led to excellent results in progression-free survival in patients with metastatic breast cancer resistant to hormone therapies. Therefore, everolimus has entered the National Comprehensive Cancer Network (NCCN) guidelines 2012 and its combination with exemestane was approved recently by the US Food and Drug Administration and the European Medicines Agency. This is the first time that a drug will have been approved for the restoration of hormone sensitivity in breast cancer.

KW - breast cancer

KW - estrogen receptor

KW - everolimus

KW - human epidermal growth factor receptor 2

KW - mammalian target of rapamycin

UR - http://www.scopus.com/inward/record.url?scp=84881050784&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84881050784&partnerID=8YFLogxK

U2 - 10.1097/CAD.0b013e328363adc5

DO - 10.1097/CAD.0b013e328363adc5

M3 - Review article

C2 - 23838677

AN - SCOPUS:84881050784

VL - 24

SP - 769

EP - 780

JO - Anti-Cancer Drugs

JF - Anti-Cancer Drugs

SN - 0959-4973

IS - 8

ER -